Ambien and Metformin Interaction: What Patients and Prescribers Need to Know

What the labels say about interactions and clearance

The Ambien label groups its drug interactions into two buckets: other CNS depressants (alcohol, benzodiazepines, opioids, tricyclic antidepressants, imipramine, chlorpromazine) and drugs that change zolpidem levels through CYP3A4 [1]. Metformin is not among the drugs it names.

The metformin hydrochloride tablet label's interaction table lists carbonic anhydrase inhibitors such as topiramate and zonisamide, drugs that reduce metformin clearance through OCT2 and MATE transporters (ranolazine, vandetanib, dolutegravir, cimetidine), alcohol, insulin and insulin secretagogues, and drugs that raise blood glucose [2]. Zolpidem is not among them.

The two drugs also leave the body differently. Rifampin cut zolpidem AUC by 73% and its peak level by 58%, while ketoconazole raised AUC by 70% and peak by 30% [1]. Metformin is not metabolized, is negligibly bound to plasma proteins, and is excreted unchanged in urine, with a plasma half-life of about 6.2 hours [2].

What the metformin label warns about

The metformin hydrochloride tablet label carries a boxed warning for lactic acidosis, a postmarketing event that has included deaths, hypothermia, hypotension and resistant bradyarrhythmias [2]. Onset is often subtle, with nonspecific symptoms the label lists as malaise, myalgias, respiratory distress, somnolence and abdominal pain; the laboratory picture includes blood lactate above 5 mmol/L, anion gap acidosis and metformin levels generally above 5 mcg/mL [2]. If lactic acidosis is suspected, the label says to stop metformin and treat in hospital, with prompt hemodialysis recommended [2].

Named risk factors include renal impairment, certain concomitant drugs, age 65 or older, radiological studies with contrast, surgery and other procedures, hypoxic states such as acute heart failure, excessive alcohol intake, hepatic impairment and mitochondrial disease [2]. The label notes that the postmarketing cases occurred primarily in patients with significant renal impairment, and it sets specific kidney rules:

• The metformin label calls for an eGFR check before starting and at least yearly, and more often in patients at risk of renal decline, including the elderly [2].
• The label contraindicates metformin at eGFR below 30 mL/min/1.73 m2 and does not recommend starting it at eGFR 30 to 45 [2].
• If eGFR later falls below 45, the label calls for reassessing the benefit and risk of continuing, and stopping if it falls below 30 [2].
• For iodinated contrast, the label calls for stopping metformin at the time of or before the procedure in patients with eGFR 30 to 60, a history of liver disease, alcoholism or heart failure, or when intra-arterial contrast is used, rechecking eGFR 48 hours later and restarting only if renal function is stable [2].

What the Ambien label warns about

Zolpidem is a sedative-hypnotic, and its label is built around the sedation. Impaired alertness and coordination can persist into the next morning even when a patient feels fully awake, and the risk rises with a higher dose, with less than 7 to 8 hours of sleep remaining, and with alcohol or other CNS depressants [1][4]. The label states that patients, particularly the elderly, are at higher risk of falls [1].

The boxed warning covers complex sleep behaviors — sleep-walking, sleep-driving and other activities while not fully awake, including preparing and eating food — which can cause serious injury or death, may happen after the first or any dose at recommended doses, and usually are not remembered [1]. Zolpidem is contraindicated in anyone who has had such an episode [1]. The label directs one dose immediately before bed with no second dose the same night, and says use with other sedative-hypnotics at bedtime or in the middle of the night is not recommended [1].

Blood sugar

The metformin label warns that hypoglycemia risk increases when metformin is combined with insulin or an insulin secretagogue such as a sulfonylurea, and that lower doses of those drugs may be needed [2]. In the label's US trial of immediate-release metformin up to 2,550 mg daily, hypoglycemia was among reactions reported in 1% to 5% of patients and more often than with placebo [2]. The Ambien label's warnings do not list a blood sugar effect; they deal with CNS depression, complex sleep behaviors, allergic reactions, abnormal thinking and behavior, depression and respiratory depression [1].

Older adults

The 2023 American Geriatrics Society Beers Criteria recommend avoiding zolpidem, eszopiclone and zaleplon in adults 65 and older (strong recommendation, moderate-quality evidence) because of delirium, falls, fractures and motor vehicle crashes alongside minimal sleep benefit [5]. The metformin label separately lists age 65 or older as a lactic acidosis risk factor and says to assess renal function more frequently in older patients [2].

Doses each label specifies

Ambien immediate-release: the recommended starting dose is 5 mg for women and 5 or 10 mg for men, with a maximum of 10 mg once daily [1]. For older adults and people with mild to moderate hepatic impairment, the Ambien label recommends 5 mg once daily [1]. Ambien CR: 6.25 mg for women and 6.25 or 12.5 mg for men, with a maximum of 12.5 mg a day, and the Ambien CR label recommends 6.25 mg once daily for older adults and people with mild to moderate hepatic impairment [3]. The label says the initial doses differ because zolpidem clearance is lower in women; FDA required the lower women's doses in January 2013 after data showed next-morning blood levels could impair driving [1][4].

Metformin immediate-release in adults starts at 500 mg twice daily or 850 mg once daily with meals, titrated to a maximum of 2,550 mg a day [2].

Non-drug option for chronic insomnia

For chronic insomnia, the American College of Physicians recommends cognitive behavioral therapy for insomnia as the initial treatment (strong recommendation, moderate-quality evidence) [6].